secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001104659-26-049733
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris reports positive Phase 1a data for ATI-052 (half-life ~45 days) and picks lichen planus for ATI-2138
--------------------------------------------------------------------------------

- ATI-052 half-life ~45 days; complete inhibition of CCL17/TARC sustained at least 20 weeks post-dose.
- Phase 1a ATI-052 well tolerated; no conjunctivitis or safety signals; dose proportional PK observed.
- Phase 1b trials in asthma and atopic dermatitis enrolling; top line results expected H2 2026.
- Phase 2b for ATI-052 targeting asthma planned for Q4 2026; Phase 2b ATI-2138 in lichen planus starts H2 2026.
- ATI-2138 is a potential first-in-class oral ITK/JAK3 inhibitor addressing pathogenic T cells; no FDA-approved LP therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926049733/0001104659-26-049733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926049733/acrs-20260428x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-049733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer